We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira (PCRX) Provides Preliminary Results for Second Quarter
Read MoreHide Full Article
Shares of Pacira BioSciences, Inc. (PCRX - Free Report) were down in pre-market trading on Tuesday after the company announced preliminary results for the second quarter of 2020. The company’s complete financial results for the period are due next month.
However, Pacira’s shares have outperformed the industry so far this year. The stock has rallied 19.8% against the industry’s decrease of 4.8%.
Second-Quarter 2020 Preliminary Results
Pacira reported preliminary net sales of $75.5 million for the quarter, ahead of the Zacks Consensus Estimate of $54.1 million. However, revenues were down 26.4% year over year as the company’s product sales were negatively impacted by the COVID-19 pandemic.
Preliminary net product sales of Exparel were $73.8 million, down 26% from $99.8 million in the year-ago quarter.
Exparel/bupivacaine liposome injectable suspension was $0.8 million compared with $0.9 million reported in the year-ago quarter. Exparel is a liposome injection of bupivacaine, indicated for a single-dose administration into the surgical site to produce postsurgical analgesia.
Newly-added product iovera system generated sales worth $1.4 million in the quarter compared with $2 million a year ago.
We remind investors that in April 2019, Pacira acquired the privately-held MyoScience, Inc. following which, it added the latter’s iovera system to its portfolio, which is highly complementary to Exparel as a non-opioid therapy. Moreover, upon closing the acquisition, the company changed its corporate name to Pacira BioSciences, Inc.
Preliminary royalty revenues came in at $0.3 million in the reported quarter compared with $0.8 million a year earlier.
Zacks Rank & Other Stocks to Consider
Pacira currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the same sector include Amneal Pharmaceuticals, Inc. (AMRX - Free Report) , Avenue Therapeutics, Inc. (ATXI - Free Report) and BioLineRx Ltd. . While Amneal Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Avenue Therapeutics and BioLineRx hold the same Zacks Rank as Pacira. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amneal Pharmaceuticals’ earnings estimates have moved 16.3% north for 2020 and 7.9% for 2021 over the past 60 days.
Avenue Therapeutics’ loss per share estimates have narrowed 21.3% for 2020 and 5.5% for 2021 over the past 60 days. The stock has increased 5.4% year to date.
BioLineRx’s loss per share estimates have narrowed 19.1% for 2020 and 13.1% for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Image: Bigstock
Pacira (PCRX) Provides Preliminary Results for Second Quarter
Shares of Pacira BioSciences, Inc. (PCRX - Free Report) were down in pre-market trading on Tuesday after the company announced preliminary results for the second quarter of 2020. The company’s complete financial results for the period are due next month.
However, Pacira’s shares have outperformed the industry so far this year. The stock has rallied 19.8% against the industry’s decrease of 4.8%.
Second-Quarter 2020 Preliminary Results
Pacira reported preliminary net sales of $75.5 million for the quarter, ahead of the Zacks Consensus Estimate of $54.1 million. However, revenues were down 26.4% year over year as the company’s product sales were negatively impacted by the COVID-19 pandemic.
Preliminary net product sales of Exparel were $73.8 million, down 26% from $99.8 million in the year-ago quarter.
Exparel/bupivacaine liposome injectable suspension was $0.8 million compared with $0.9 million reported in the year-ago quarter. Exparel is a liposome injection of bupivacaine, indicated for a single-dose administration into the surgical site to produce postsurgical analgesia.
Newly-added product iovera system generated sales worth $1.4 million in the quarter compared with $2 million a year ago.
We remind investors that in April 2019, Pacira acquired the privately-held MyoScience, Inc. following which, it added the latter’s iovera system to its portfolio, which is highly complementary to Exparel as a non-opioid therapy. Moreover, upon closing the acquisition, the company changed its corporate name to Pacira BioSciences, Inc.
Preliminary royalty revenues came in at $0.3 million in the reported quarter compared with $0.8 million a year earlier.
Zacks Rank & Other Stocks to Consider
Pacira currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the same sector include Amneal Pharmaceuticals, Inc. (AMRX - Free Report) , Avenue Therapeutics, Inc. (ATXI - Free Report) and BioLineRx Ltd. . While Amneal Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Avenue Therapeutics and BioLineRx hold the same Zacks Rank as Pacira. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amneal Pharmaceuticals’ earnings estimates have moved 16.3% north for 2020 and 7.9% for 2021 over the past 60 days.
Avenue Therapeutics’ loss per share estimates have narrowed 21.3% for 2020 and 5.5% for 2021 over the past 60 days. The stock has increased 5.4% year to date.
BioLineRx’s loss per share estimates have narrowed 19.1% for 2020 and 13.1% for 2021 over the past 60 days.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>